Recombinant sh-Oligopeptide-1 (EGF)
Recombinant human EGF (sh-Oligopeptide-1) in a stabilizing aqueous suspension for cosmetic renewal serums.*
Suspension stabilizers in the shipped bulk are processing aids and are not declared on the finished-product INCI when the material is used as directed. See SDS for details.
sh-Oligopeptide-1 · CAS 62253-63-8 · ~6,045 Da
Epidermal Growth Factor (EGF) binds EGFR on keratinocytes and fibroblasts, signaling renewal pathways studied in wound-healing and cosmetic skin-science literature. We ship bioengineered sh-Oligopeptide-1 in a stabilizing suspension that helps preserve protein integrity and extend shelf life during refrigerated storage.*
We ship recombinant EGF in a stabilizing aqueous suspension at two strengths - standard 1X (0.016%) for typical cosmetic dilution workflows, or a 5X lab concentrate (0.08%) when you want five times the protein loading in the same pack. The suspension helps protect the active during refrigerated storage and reduce deterioration - see SDS for composition details.*
These attributes are assessments based on the ingredient deck and the supplier information available to us. They are not third-party certifications. If your finished product requires a specific certified status, please reach out and we’ll walk through what we can document.
Every lot is produced to order in our AI-powered robotic factory. Nothing sits on a warehouse shelf going stale - you get a date-of-manufacture-fresh batch every time.
* Structure/function statements based on published cosmetic in-vitro studies. Not evaluated for, and not intended to, diagnose, treat, cure, or prevent any disease.
Epidermal Growth Factor (sh-Oligopeptide-1) is widely cited in skin-science literature for keratinocyte renewal, EGFR signaling, and cosmetic recovery positioning. These are independent, third-party papers we link for formulators evaluating mechanism, tolerability, and published panel data. We did not conduct this research and do not guarantee replication in your finished formula.
Open-label three-month facial study of a barley-produced human-like EGF serum. Investigators reported statistically significant improvements in the appearance of fine lines, texture, pore size, and dyschromia.
Twelve-week comparison in 60 women with mild-to-moderate photoaging. The recombinant EGF plus crosslinked HA regimen was preferred for smoothness and firmness by week 2, with further investigator-rated gains in fine lines, radiance, and overall appearance by week 12.
Reviews published cosmetic trials that treat sh-Oligopeptide-1 as EGF-equivalent and argues that preclinical bioactivity of cosmetic-grade sh-oligopeptide-1 is not established. Included as due-diligence reading for formulators evaluating EGF-class actives.
These citations are provided for informational and formulation-research purposes only. Study designs, concentrations, vehicle systems, and populations vary and may not match the suspensions on this page. Published results do not constitute FDA or EU cosmetic claim substantiation for your brand. Always review the primary literature and consult your regulatory counsel before making structure/function statements on finished products.
This is the bulk composition as it ships. Updates dynamically when you change the strength above. The active line shows the EGF loading at the selected concentration. Suspension stabilizers in the shipped bulk protect the active during storage and are not declared on the finished-product cosmetic INCI when the protein is reconstituted / diluted into your formula as directed. Full stabilizer identity and concentration are on the SDS.
SDS + TDS are issued per strength. Links swap when you change concentration above. COA is batch-specific and ships with the order.
Statements contained on this page (including any marked with *) have not been evaluated by the U.S. Food and Drug Administration. This product is a cosmetic raw material and is not intended to diagnose, treat, cure, or prevent any disease.
